Klinikum Wuerzburg Mitte gGmbH — Clinical Trial Site

26 Registered trials

10 Currently recruiting

Organisation

Klinikum Wuerzburg Mitte gGmbH

Location

Wuerzburg, Germany

Identifier

ORG-100048407

Address

Salvatorstrasse 7, Frauenland, 97074, Germany

Departments

2609:Medizinische Klinik mit Schwerpunkt Pneumologie & Beatmungsmedizin
Campus Juliusspital, Institute of Laboratory Medicine and Vaccination Centre
Innere - Schwerpunkt Pneumologie
Innere Medizin
Institut fuer Labormedizin und Impfzentrum
Institute of Laboratory Medicine and Vaccination Centre
Julius Hospital
Klinik für Neurologie
Klinik für Neurologie & Neurologische Frührehabilitation (Phase B)
Klinik für Neurologie und Neurologische Frührehabilitation
Klinikum für Neurologie
Medizinische Klinik - Schwerpunkt Pneumologie
Medizinische Klinik mit Schwerpunkt Pneumologie & Beatmungsmedizin
Missionsärztliche Klinik
n/a
Neurologie
Neurology
Pneumologie und Beatmungsmedizin
Pneumonologie und Beatmungsmedizin
Pulmonology
Schwerpunkt Pneumologie u. Beatmungsmedizin
Standort Missioklinik

Clinical trials at this site (26)

Search interface

A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Stage I adenocarcinoma non-small cell lung cancer (NSCL 5
A Study of Repotrectinib versus Crizotinib in Participants with Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-po… Recruiting

2023-505604-32-00 Non small cell lung cancer (NSCLC) 5 2024-01-24
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-11-28
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Generalized Myasthenia Gravis 5 2025-11-13
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting

2024-518365-10-00 Previously Untreated Advanced or Metastatic Non-Squamou 5 2025-10-28
Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368, a FAAH/MAGL Inhibitor, in Participants with Multiple Sclerosis Spasti… Recruiting

2024-517745-14-00 Multiple Sclerosis Spasticity 4 2025-09-24
A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-514281-39-00 Metastatic Squamous Non-small Cell Lung Cancer Whose Tu 5 2025-02-14
A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot… Recruiting

2024-515008-38-00 Metastatic Non-squamous Non-small Cell Lung Cancer Whos 5 2025-02-14
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients w… Recruiting

2023-507064-39-00 generalized Myasthenia Gravis 5 2024-09-26
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid … Recruiting

2023-505065-91-00 Advanced or Metastatic Solid Tumors including EGFR-muta 4 2023-01-30
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients with previously treated KRAS G12C-positive… Ended

2024-510908-37-00 KRAS G12C-Positive Advanced or Metastatic Non-Small Cel 5 2024-08-28
An extension and crossover vaccination study on the immune response and safety of a vaccine against respiratory syncytial virus given to adu… Ended

2023-509762-38-00 Respiratory Syncytial Virus Infections 5 2024-08-01
A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either… Ended

2023-503357-35-00 Non-small Cell Lung Cancer (NSCLC) 4 2024-03-20
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09
Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis. Ended

2023-508284-77-00 Generalized Myasthenia Gravis with autoantibodies again 5 2022-11-16
A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended

2023-509943-28-00 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR 5 2022-05-18
Radiation during Osimertinib Treatment: a Safety and Efficacy Cohort Study (ROSE) Ended

2022-503028-29-01 Patients with stage IV EGFR-mutation positive NSCLC tar 4 2021-12-14
Immunogenicity, safety, reactogenicity and persistence of an investigational respiratory syncytial virus (RSV) vaccine in adults aged 60 yea… Ended

2024-512291-34-00 Respiratory Syncytial Virus Infections 5 2021-02-22
A trial to learn how well osimertinib (AZD9291) works to prevent cancer from coming back after surgery and how safe it is compared to the pl… Ended

2023-506524-82-00 Stage IB-IIIA non-small cell lung carcinoma, with a cen 5 2015-10-21
A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis Ended

2023-510249-79-00 Progressive pulmonary fibrosis (PPF) 4 2024-09-10
A study on the immune response and safety of vaccine against respiratory syncytial virus given to adults 18 to 49 years of age at increased … Ended

2023-510190-34-00 Respiratory Syncytial Virus Infections 5 2024-06-04
Phase 3 Study to Assess Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasth… Ended

2024-512258-91-00 Generalized Myasthenia Gravis (gMG) 5 2023-02-03
A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant… Ended

2023-509078-45-00 Multiple sclerosis 4 2022-12-19